Bafna Pharmaceuticals Limited reported strong Q3 FY26 results with revenue of ₹3,828.58 lakhs, up 15.36% YoY, and net profit of ₹183.69 lakhs, representing 93.87% growth from Q3 FY25. Nine-month performance showed revenue of ₹10,837.80 lakhs with net profit surging 193.88% to ₹835.06 lakhs. The company faces regulatory challenges including GST demands totaling ₹566.56 lakhs but remains confident of favorable outcomes through legal appeals.
Bafna Pharmaceuticals Reports Strong Q3 FY26 Performance with 93.87% Profit Growth
